Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 2 | Alzheimer's Research & Therapy

Fig. 2

From: A digital enzyme-linked immunosorbent assay for ultrasensitive measurement of amyloid-β 1–42 peptide in human plasma with utility for studies of Alzheimer’s disease therapeutics

Fig. 2

Western blot of amyloid-β 1–42 peptide (Aβ1–42) peptide standards after 3D6 antibody detection following quantitative acid gel electrophoresis. Lanes 1–5 (left to right),1–42 reference standard from Lilly with amounts of 1, 0.5, 0.25, 0.125, and 0.0625 ng, respectively, loaded into each well. Lanes 6–8 show three replicates of the diluted Quanterix Aβ1–42 standard. Lanes 9–11 show three replicates of the diluted INNOTEST® Aβ1–42 standard. Lanes 12 and 13 show two replicates of another Lilly substock of Aβ1–42 reference standard. From lane 6 to lane 13, 0.25 ng of each Aβ1–42 peptide was loaded per well, based upon their stated concentrations

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193